Figlin says drugs like lenvatinib, everolimus, and cabozantinib have emerged in recent years as possible first-line therapies for RCC.
Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, talks about the increasingly complicated treatment paradigm for renal cell carcinoma (RCC).
Figlin says drugs like lenvatinib, everolimus, and cabozantinib have emerged in recent years as possible first-line therapies for RCC. He references a recent study published by The New England Journal of Medicine, where patients with advanced RCC had an improved overall survival rate of 5.4 months while on nivolumab versus everolimus.
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More